Metformin use doesn't cut incidence of bladder cancer

Metformin use doesn't cut incidence of bladder cancer

(HealthDay)—For patients with type 2 diabetes, metformin use is not associated with a significantly reduced risk of bladder cancer, according to a study published online Feb. 4 in Diabetes Care.

Ronac Mamtani, M.D., from the University of Pennsylvania in Philadelphia, and colleagues conducted a involving 87,600 patients with in The Health Improvement Network database. The incidence of in new users of and sulfonylureas was examined. Metformin or sulfonylurea use was treated as a time-dependent variable. The authors hoped to address the time-related biases that may have affected previous studies relating to the effect of metformin on cancer risk.

The researchers identified 196 incident bladder cancers in the metformin cohort and 66 in the sulfonylurea cohort. The risk of bladder cancer was not significantly decreased in association with metformin use (hazard ratio, 0.81; 95 percent confidence interval [CI], 0.60 to 1.09). The correlation was not affected by sex (P for interaction = 0.20). There was also no reduction in bladder cancer risk with increased duration of metformin use relative to use of sulfonylureas (three to less than four years of use: 0.57 [95 percent CI, 0.25 to 1.34]; four to less than five years of use: 0.93 [95 percent CI, 0.30 to 2.85]; and five or more years of use: 1.18 [95 percent CI, 0.44 to 3.19]; P for trend = 0.26).

"Similar methods should be used to study other cancers that have previously been identified as potentially preventable with metformin," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Sulfonylureas up cardio events versus metformin

date Nov 07, 2012

(HealthDay)—Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue ...

Metformin may increase risk of cognitive impairment

date Sep 21, 2013

(HealthDay)—Metformin may increase the risk of cognitive impairment in patients with diabetes; however, calcium supplementation may attenuate this risk, according to research published online Sept. 5 in ...

Lung cancer risk unaffected by metformin use in diabetes

date Aug 30, 2012

(HealthDay)—Patients with type 2 diabetes who take metformin do not have a reduced risk of lung cancer, in contrast to previous observational studies, according to a study published online Aug. 24 in Diabetes Care.

Recommended for you

Spicy treatment the answer to aggressive cancer?

date Jul 03, 2015

It has been treasured by food lovers for thousands of years for its rich golden colour, peppery flavour and mustardy aroma…and now turmeric may also have a role in fighting cancer.

Cancer survivors who smoke perceive less risk from tobacco

date Jul 02, 2015

Cancer survivors who smoke report fewer negative opinions about smoking, have more barriers to quitting, and are around other smokers more often than survivors who had quit before or after their diagnosis, according to a ...

Melanoma mutation rewires cell metabolism

date Jul 02, 2015

A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme, researchers at Winship Cancer Institute of Emory University have discovered.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.